NeuroRestorative Annual Medical Director Conference 2023

This enduring activity will bring together Medical Directors at all NeuroRestorative facilities. It will address three areas of clinical practice that are among those confronted by NeuroRestorative Medical Directors: Spasticity among patients with traumatic brain injury, stroke, and other neurologic disorders & Stem Cells in the Treatment of CNS disorders and Paroxysmal sympathetic hyperactivity (PSH) after traumatic brain injury and other brain disorders in children and adults.

Target Audience

This activity is intended for Medical Directors (MDs, DOs), psychologists (PhDs, PsyDs), and nurse practitioners (NPs) who practice at NeuroRestorative facilities in 28 states across the United States.

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. List the indications for cryoneurolysis for the treatment of spasticity.
  2. Summarize the current state-of-the-science of stem cell treatment for CNS disorders.
  3. List medications that can be used to treat paroxysmal sympathetic hyperactivity in pediatric patients.
  4. Describe the pharmacologic approach to depression following brain injury.

Additional Information

Provided by: 

NeuroRestorative & Mass General Brigham

Course summary
Available credit: 
  • 3.00 AMA PRA Category 1 Credit™
  • 3.00 Participation
Course opens: 
Course expires: 

Mel Glenn, MD - Course Director
National Medical Director, NeuroRestorative
Chief, Division of Brain Injury Rehabilitation, Dept. of Physical Medicine & Rehabilitation - Spaulding Rehabilitation Network
Associate Professor of Physical Medicine and Rehabilitation, Harvard Medical School

Bill Duffy
President, NeuroRestorative

Shawn Rowles, MD
Medical Director, NeuroRestorative 4 Kids
Las Vegas, NV

Sean Savitz, MD
Professor of Neurology, University of Texas Health Science Center (UTHealth)
Frank M. Yatsu Chair in Neurology, University of Texas Health Science Center (UTHealth)
Houston, TX

Lu Sutherland, RN, MSN, PTA
Vice President of Quality Improvement, NeuroRestorative

Paul Winston, MD
Physiatrist, Victoria Peripheral Nerve & Spasticity Clinic
Medical Director, Rehabilitation & Transitions - Island Health
Co-Founder, Canadian Advances in Neuro-Orthopedics for Spasticity Congress
Clinical Associate Professor, University of British Columbia
Victoria, British Columbia, Canada


Mitigation Strategies
Mass General Brigham has implemented a process to mitigate relevant financial relationships for this continuing education (CE) activity to help ensure content objectivity, independence, fair balance and ensure that the content is aligned with the interest of the public. 

The following planners have reported no relevant financial relationship with an ineligible company:
Mel Glenn, MD
Lu Sutherland, RN, MSN, PTA

The following speakers have reported no relevant financial relationships an ineligible company:
Mel Glenn, MD
Lu Sutherland, RN, MSN, PTA
Shawn Rowles, MD

The following speakers have reported a relevant financial relationship with an ineligible company:
Sean Savitz, MD
Consultant: ReNeuron, Lumosa, Desk Therapeutics, KM Pharma, Neurexcell, Abbvie, Neurastasis, ArunA, Simcere

Paul Winston, MD
Educational & research funding: Pacira, AbbVie, Ipsen, Merz
Travel Grants: Pacira, AbbVie, Ipsen, Merz
Advisory Boards: Pacira, AbbVie, Ipsen, Merz

In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Mass General Brigham designates this enduring activity for a maximum of 3.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 3.00 AMA PRA Category 1 Credit™
  • 3.00 Participation


Please login or register to take this course.